The Latest Cardiac and Vascular News
SUNNYVALE, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) — BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces the activation of Ottawa Heart Institute, the first Canadian clinical investigational site for the CardiAMP® Cell Therapy Heart Failure Trial. “The Ottawa Heart […]
Evaluated doses of YUTREPIA™ (treprostinil) inhalation powder from 26.5 mcg to 212 mcg which are comparable to 3 to 24 breaths of nebulized Tyvaso® per session Achieved therapeutic levels by Month 2 and continued to titrate to higher levels for approximately one year on average before rolling into extension trial Safety […]
By combining AI-guided echocardiograms and Virtual-First cardiology care, the new partnership enables early disease identification and management for patients from the comfort of their homes BRISBANE, Calif. and NEW YORK, July 28, 2022 /PRNewswire/ — Caption Health, the leader in providing services and AI to improve heart ultrasound access, and Heartbeat Health, the nation’s largest Virtual […]
Phase 2b RE-THINC ESRD study of fesomersen met its primary endpoint in patients with end-stage renal disease on hemodialysis Fesomersen demonstrated substantial and statistically significant reductions in Factor XI activity levels Fesomersen, a novel Factor XI antisense inhibitor designed to prevent thrombosis, was safe and well-tolerated in the study with up to […]
More Effective SofPulse® Results Compared With Bioelectronics RecoveryRx® Los Angeles, CA, July 28, 2022 (GLOBE NEWSWIRE) — Endonovo Therapeutics Inc. (OTCQB:ENDV) today released superior comparative results for its SofPulse® medical device for post-operative pain relief compared with Bioelectronics Corporation’s RecoveryRx®. The medical treatment comparisons were clinically evaluated based on three clinical trials for RecoveryRx® and […]
— BROOKLYN evaluates obicetrapib as an adjunct to diet and maximally tolerated lipid lowering therapy in patients requiring additional lowering of low-density lipoprotein cholesterol (LDL-C) — — Company expects to report initial data in 2024 — — With BROOKLYN underway, both pivotal trials designed to support a potential LDL-lowering approval […]
NDA supported by SOLOIST-WHF and SCORED Global Phase 3 Program Evaluating Sotagliflozin in Almost 12,000 People THE WOODLANDS, Texas, July 27, 2022 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review and filed its New Drug Application (NDA) for […]
Data Highlighted in Poster Presentation at the American Society for Preventive Cardiology Congress on CVD Prevention LOUISVILLE, Ky.–(BUSINESS WIRE)–The Family Heart Foundation, a leading research and advocacy organization, completed an analysis of its large U.S. Family Heart DatabaseTM showing that while the percentage of patients diagnosed with familial hypercholesterolemia (FH) has increased […]
VANCOUVER and MINNEAPOLIS, July 26, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today announced the United States Food and Drug Administration (“FDA”) has approved a protocol supplement to the COSIRA-II Investigational Device Exemption (“IDE”) Trial. The approval expands the number of patients eligible for treatment […]
— Preclinical model data expected to support development of small diameter HAV to treat patients with coronary artery disease– — Small-diameter HAV observed to maintain patency and exhibit host-cell remodeling at six months post-implantation in a non-human primate model– –Results presented at American Heart Association Basic Cardiovascular Sciences Scientific Sessions 2022 […]
